Holen Sie sich die Stockscreener-App
1.62
0.61%
-0.010
Handel nachbörslich:
1.62
Schlusskurs vom Vortag:
$1.63
Offen:
$1.58
24-Stunden-Volumen:
73,065
Relative Volume:
0.64
Marktkapitalisierung:
$120.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.5176
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
+0.00%
1M Leistung:
+3.85%
6M Leistung:
-19.00%
1J Leistung:
+1.89%
1-Tages-Spanne:
$1.53
$1.625
1-Wochen-Bereich:
$1.53
$1.75
52-Wochen-Spanne:
$1.415
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
(302) 295-3800
Adresse
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.62 | 121.46M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Custom watchlist performance reports with Inhibikase Therapeutics Inc.July 2025 Big Picture & Step-by-Step Swing Trade Plans - newser.com
Can Inhibikase Therapeutics Inc. stock maintain operating marginsQuarterly Profit Review & Daily Growth Stock Investment Tips - newser.com
How to build a custom watchlist for Inhibikase Therapeutics Inc.July 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Using data tools to time your Inhibikase Therapeutics Inc. exit2025 Momentum Check & Reliable Entry Point Trade Alerts - newser.com
Pattern recognition hints at Inhibikase Therapeutics Inc. upside2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
How to read the order book for Inhibikase Therapeutics Inc.Market Rally & Consistent Growth Equity Picks - newser.com
Can trapped investors hope for a rebound in Inhibikase Therapeutics Inc.Market Rally & AI Enhanced Execution Alerts - newser.com
Developing predictive dashboards with Inhibikase Therapeutics Inc. dataMarket Risk Summary & Technical Confirmation Alerts - newser.com
Has Inhibikase Therapeutics Inc. formed a bullish divergenceJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com
Why Inhibikase Therapeutics Inc. stock is a must watch in 2025Quarterly Trade Summary & AI Forecasted Entry and Exit Points - newser.com
Why Inhibikase Therapeutics Inc. is moving today2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Inhibikase Therapeutics Inc.Earnings Miss & Low Drawdown Trading Techniques - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock could be top winnerWeekly Market Summary & Real-Time Market Sentiment Reports - newser.com
Published on: 2025-10-12 03:48:12 - newser.com
Will Inhibikase Therapeutics Inc. stock go up soon2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Evaluating Inhibikase Therapeutics Inc. with trendline analysis2025 Fundamental Recap & Precise Trade Entry Recommendations - newser.com
How geopolitical risks impact Inhibikase Therapeutics Inc. (IQT0) stock2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock is a strong analyst pick2025 Short Interest & Daily Profit Focused Screening - newser.com
Is this a good reentry point in Inhibikase Therapeutics Inc.Trade Volume Summary & Free Growth Oriented Trading Recommendations - newser.com
Inhibikase Therapeutics (NASDAQ:IKT) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Inhibikase Therapeutics Inc Stock Analysis and ForecastHigh Dividend Yield Stocks & Breakthrough Profit Margins - earlytimes.in
What drives Inhibikase Therapeutics Inc IQT0 stock priceVolume Analysis Techniques & Free Explosive Trading Growth - earlytimes.in
Inhibikase Therapeutics Inc. stock outlook for YEARQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
Market reaction to Inhibikase Therapeutics Inc.’s recent news2025 Market Outlook & Fast Entry and Exit Trade Plans - newser.com
What MACD and RSI say about Inhibikase Therapeutics Inc.2025 Retail Activity & Safe Entry Point Alerts - newser.com
Leading vs lagging indicators on Inhibikase Therapeutics Inc. performance2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Inhibikase Therapeutics (NYSE:IKT) vs. LadRx (OTCMKTS:CYTR) Critical Contrast - Defense World
Has Inhibikase Therapeutics Inc. found a price floorPortfolio Return Summary & Short-Term Trading Alerts - newser.com
Using flow based indicators on Inhibikase Therapeutics Inc.CEO Change & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-10-03 06:03:22 - newser.com
Heatmap analysis for Inhibikase Therapeutics Inc. and competitorsMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com
How to monitor Inhibikase Therapeutics Inc. with trend dashboardsPortfolio Profit Report & Free Community Consensus Stock Picks - newser.com
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibikase Therapeutics Inc-Aktie (IKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):